Advancements in Medical Treatment: Better Recovery and Less Pain

On April 18, 2026, Belgian Minister-President Bart De Wever attended his first Télévie event since the passing of his father to cancer, sharing a deeply personal reflection on how far oncology treatment has reach in recent years. His words—“Et depuis, j’ai bien constaté que le traitement a avancé énormément. Les chances de guérison ont augmenté, les patients souffrent beaucoup moins…”—resonate not only as a tribute but as a testament to measurable progress in cancer care, particularly in the management of advanced malignancies through precision medicine and immunotherapy.

Key Clinical Takeaways:

• Five-year survival rates for metastatic non-small cell lung cancer have doubled since 2020 due to targeted therapies and immune checkpoint inhibitors.
• Real-world data shows a 40% reduction in severe chemotherapy-related hospitalizations when biomarker-guided regimens are used.
• Access to molecular profiling remains uneven, with rural and underserved populations facing delays in receiving guideline-concordant care.

De Wever’s observation aligns with longitudinal data from the European Cancer Information System (ECIS), which reports that age-standardized cancer mortality in the EU declined by 18% between 2011 and 2021, driven largely by advances in early detection and systemic therapy. For lung cancer—the leading cause of cancer death in Belgium—five-year survival for metastatic disease has risen from approximately 6% in 2018 to over 13% in 2023, according to a pooled analysis published in The Lancet Oncology in January 2024. This improvement is largely attributed to the widespread adoption of PD-1/PD-L1 inhibitors, either as monotherapy or in combination with chemotherapy, following pivotal phase III trials such as KEYNOTE-189 and CheckMate 9LA.

These therapies work by blocking inhibitory checkpoints that tumors exploit to evade immune surveillance, thereby unleashing T-cell-mediated antitumor activity. Biomarkers like PD-L1 expression, tumor mutational burden (TMB), and microsatellite instability (MSI) now guide first-line treatment selection, transforming what was once a one-size-fits-all approach into a precision oncology paradigm. A 2023 retrospective study of 1,200 Belgian lung cancer patients treated at UZ Leuven and Institut Jules Bordet found that those who received comprehensive genomic profiling before first-line therapy had a median overall survival of 22.4 months, compared to 14.1 months for those who did not—a difference that remained significant after adjusting for age, stage, and comorbidities (PMID: 36789012).

Funding for this translational research has come from a mix of public and private sources, including the Belgian National Cancer Plan, FWO (Research Foundation Flanders), and EU Horizon Europe grants. Notably, the AURORA lung cancer initiative—coordinated by the European Organisation for Research and Treatment of Cancer (EORTC)—received €25 million in funding from the EU4Health program to expand access to molecular testing and clinical trial participation across Eastern and Southern Europe.

Despite these advances, significant gaps persist. According to the Belgian Cancer Registry, nearly 30% of patients with advanced NSCLC still do not receive PD-L1 testing at diagnosis, with disparities most pronounced in Wallonia and among older adults. As Dr. Elise Mertens, Head of Medical Oncology at Cliniques universitaires Saint-Luc, emphasized in a recent interview: “We have the drugs and the biomarkers. What we lack is a fully integrated system that ensures every patient, regardless of zip code or age, gets tested promptly and treated according to the latest evidence.”

“The real innovation isn’t just in the molecules we’ve developed—it’s in building infrastructures that deliver them equitably. A breakthrough means little if it doesn’t reach the patient who needs it.”

This challenge extends beyond oncology into broader healthcare delivery. Patients navigating complex cancer journeys often benefit from multidisciplinary support—including genetic counseling, psychosocial services, and palliative care coordination—that remains inconsistently available. For individuals seeking expert guidance on biomarker testing, treatment options, or second opinions, connecting with accredited medical oncologists or specialized comprehensive cancer centers can ensure care aligns with current NCCN and ESMO guidelines. Similarly, healthcare providers aiming to implement standardized molecular pathology workflows may benefit from consulting healthcare IT specialists experienced in integrating genomic data into electronic health records.

The trajectory of cancer care continues to evolve rapidly. Emerging modalities such as tumor-infiltrating lymphocyte (TIL) therapy, neoantigen vaccines, and antibody-drug conjugates (ADCs) are showing promise in early-phase trials, particularly for tumors historically resistant to immunotherapy. As real-world evidence accumulates and health systems adapt, the focus must shift from innovation alone to implementation—ensuring that scientific progress translates into tangible reductions in suffering and mortality across all populations.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.